<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00729209</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-797-103</org_study_id>
    <nct_id>NCT00729209</nct_id>
  </id_info>
  <brief_title>A Study of ARRY-371797 in Patients With Rheumatoid Arthritis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Array BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Array BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study, involving a 29-day treatment period, designed to evaluate the
      pharmacokinetics and the effectiveness of investigational study drug ARRY-371797 in treating
      rheumatoid arthritis in patients receiving stable doses of methotrexate, and to further
      evaluate the drug's safety. Approximately 30 patients from the US will be enrolled in this
      study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize the pharmacokinetics (PK) of the study drug and a metabolite in terms of plasma concentrations.</measure>
    <time_frame>29 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests, vital signs and electrocardiograms.</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the efficacy of study drug (versus placebo) in terms of cross-reactive protein (CRP), the Patient's Assessment of Arthritis Pain (100 mm visual analog scale [VAS]) and urinary N-Telopeptide Cross-Links (NTx).</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>ARRY-371797 (Schedule 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ARRY-371797 (Schedule 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARRY-371797, p38 inhibitor; oral</intervention_name>
    <description>multiple dose, single schedule</description>
    <arm_group_label>ARRY-371797 (Schedule 1)</arm_group_label>
    <arm_group_label>ARRY-371797 (Schedule 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo; oral</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Diagnosed with rheumatoid arthritis (RA) at least 3 months prior to study start based
             upon the American College of Rheumatology (ACR) 1987 Revised Criteria.

          -  On a stable weekly dose of both methotrexate (MTX) (10 - 25 mg/week inclusively;
             either oral or parenteral) and folate (≥ 5 mg weekly ) for ≥ 6 weeks prior to study
             start and is willing to continue on these regimens for the duration of the study.

          -  Meets the ACR 1991 Revised Criteria for Global Functional Status in RA, Class I, II,
             or III.

          -  Completed an appropriate washout period if treated with specified therapies.

          -  Patients may continue on specified stable background therapy for RA (doses should be
             stable for at least 6 weeks prior to the first dose of study drug, unless the patient
             stops due to documented disease improvement, with Sponsor approval).

          -  Additional criteria exist.

        Key Exclusion Criteria:

          -  Diagnosis of any other inflammatory or non-inflammatory arthritis (e.g.
             spondyloarthritis; fibromyalgia, psoriatic arthritis, crystal-proven gout) that may
             interfere with disease activity assessments and/or clinically apparent osteoarthritis
             which would affect subsequent efficacy measures.

          -  Has received any of the following prior treatments:

               1. Within 4 weeks of first dose of study drug: anakinra (Kineret®), etanercept
                  (Enbrel®);

               2. Within 8 weeks of first dose of study drug: infliximab (Remicade®), adalimumab
                  (Humira®), leflunomide (Arava®);

               3. At any time: rituximab (Rituxan®), alemtuzumab (CamPath®), any experimental B
                  cell targeting agents.

          -  Treatment with potent CYP3A inhibitors or inducers, disease-modifying antirheumatic
             drugs (DMARDs) and/or biologic response modifiers (BRMs) during the study.

          -  Additional criteria exist.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinic for Rheumatic Diseases</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Valley Arthritis Center, Ltd</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woodland International Research Group</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NUCATS Institute, Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Sciences Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Clinical Research Group</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2008</study_first_submitted>
  <study_first_submitted_qc>August 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2008</study_first_posted>
  <last_update_submitted>April 23, 2012</last_update_submitted>
  <last_update_submitted_qc>April 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

